Journal article
Expanding PPMI through Remote Data Acquisition and Analysis: Early Success and Future Growth with myPPMI
Annals of neurology
05/10/2026
DOI: 10.1002/ana.78245
PMID: 42108656
Abstract
The creation and ongoing development of the myPPMI platform (see Stanley et al in this issue), has enabled the Parkinson's Progression Markers Initiative (PPMI) to expand our research efforts to acquire additional data, engage a large number of participants, and reduce participant burden to enable long‐term follow‐up. We now review specific virtual and remote studies and sub‐studies including Found, PPMI Online, and PPMI Cognitive that PPMI has developed to enhance participant engagement and enable remote data collection. FOUND in PPMI was initiated before myPPMI and continues to serve as a model for remote participant engagement. FOUND maintains longitudinal contact, reducing study attrition, and preserving data continuity. PPMI Online, now part of myPPMI, enables low‐burden, participant‐reported data collection, reduces geographic barriers, and enables sub‐studies of less common subgroups. Cognitive testing is another study within myPPMI to assess longitudinal cognition. myPPMI, a global web‐based portal, introduces precision recruitment, real‐time eligibility matching, and inclusive design. Together, these innovations enable remote and hybrid recruitment and study conduct, reduce logistical and economic barriers, and advance scalable, participant‐centered research to transform the landscape of Parkinson's disease studies across populations. ANN NEUROL 2026
Details
- Title: Subtitle
- Expanding PPMI through Remote Data Acquisition and Analysis: Early Success and Future Growth with myPPMI
- Creators
- Caroline M. Tanner - University of California, San FranciscoCraig E. Stanley - Institute for Neurodegenerative DisordersEthan G. Brown - University of California, San FranciscoLana M. Chahine - University of PittsburghDaniel Weintraub - University of PennsylvaniaRoseanne D. Dobkin - Rutgers, The State University of New JerseyWerner Poewe - Innsbruck Medical UniversityEduardo Tolosa - Biomedical Research Networking Center on Neurodegenerative DiseasesConnie Marras - University Health NetworkSebastian Schade - Universitätsmedizin GöttingenKelvin L. Chou - Michigan MedicineNicola Pavese - NIHR Newcastle Biomedical Research CentreChristopher S. Coffey - University of IowaMichael C. Brumm - University of IowaRyan Kurth - University of IowaAlastair J. Noyce - Queen Mary University of LondonPaulina Gonzalez-Latapi - Northwestern UniversityAuldyn Matthews-McGee - Institute for Neurodegenerative DisordersMonica Korell - University of California, San FranciscoCheryl Meng - University of California, San FranciscoXuejie Chen - University of California, San FranciscoLynn Racelo - University of California, San FranciscoJillian Ricci - Institute for Neurodegenerative DisordersCailey Fitzgerald - Institute for Neurodegenerative DisordersNichole H. Rigby - Institute for Neurodegenerative DisordersJohn A. Battles - Institute for Neurodegenerative DisordersJacqueline K. Carley - Institute for Neurodegenerative DisordersZeina Singh - Institute for Neurodegenerative DisordersLaura Kruchkow - Institute for Neurodegenerative DisordersBridget A. McMahon - Institute for Neurodegenerative DisordersEmily Flagg - Institute for Neurodegenerative DisordersLynell P. Lemon - Institute for Neurodegenerative DisordersJohn‐Michael Talarico - Institute for Neurodegenerative DisordersKathryn Brodkin - Institute for Neurodegenerative DisordersChristina Destro - Michael J. Fox FoundationMaggie McGuire Kuhl - Michael J. Fox FoundationKimberly Fabrizio - Institute for Neurodegenerative DisordersKenneth Marek - Institute for Neurodegenerative DisordersThomas F. Tropea - Institute for Neurodegenerative DisordersParkinson's Progression Markers Initiative
- Resource Type
- Journal article
- Publication Details
- Annals of neurology
- DOI
- 10.1002/ana.78245
- PMID
- 42108656
- ISSN
- 0364-5134
- eISSN
- 1531-8249
- Publisher
- Wiley
- Grant note
- Michael J. Fox Foundation for Parkinson's Research AbbVie BIAL Critical Path Institute Edmond J. Safra Foundation Eli Lilly, Gain Therapeutics GE HealthCare Voyager Therapeutics Weston Family Foundation
PPMI-a public-private partnership-is funded by The Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Alamar Biosciences, Aligning Science Across Parkinson's, Arrowhead Pharma, AskBio, BIAL, BioArctic, Biohaven, BlueRock Therapeutics, Bristol-MyersSquibb, Calico Labs, Capsida Biotherapeutics, Critical Path Institute, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Insitro, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Neumora, Neuron23, Novartis, Regeneron, Roche, Sanofi, Tenvie, UCB, VanquaBio, Voyager Therapeutics, and the Weston Family Foundation.
- Language
- English
- Electronic publication date
- 05/10/2026
- Academic Unit
- Biostatistics
- Record Identifier
- 9985163702302771
Metrics
1 Record Views